Live panel discussion will explore
considerations with respect to positioning of cell-based and
other
emerging immunotherapy platforms in solid tumors
AUSTIN,
Texas, May 9, 2022 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a
clinical-stage gene therapy company focused on developing
life-changing therapies for patients with cancer and diabetes,
today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert
panelist at the 33rd Annual Cancer Progress Conference,
taking place virtually May 10-12,
2022.
The live panel discussion, titled, "Into the Unknown – Bringing
New Modalities into Solid Tumors," will take place on Thursday, May 12 at 9 a.m.
ET. This panel will explore considerations with respect to
positioning of cell-based and other emerging immunotherapy
platforms in solid tumors. Topics to be addressed by this panel
include the current state of play, alignment of science with
evolving unmet needs and perceived paths toward value inflection
within different solid tumor markets.
Since 1989, Cancer Progress is the only oncology conference that
facilitates discussions of scientific progress within the context
of development, regulatory, clinical, commercial and investment
perspectives over three days of provocative, informative panel
discussions. The conference will feature pivotal topics, frank
discussions, vigorous debate, opportunities for audience questions
and comments, and a partnering platform to enable meaningful
connections and meetings with innovators, developers and
investors.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes. Genprex's technologies are
designed to administer disease-fighting genes to provide new
therapies for large patient populations with cancer and diabetes
who currently have limited treatment options. Genprex works with
world-class institutions and collaborators to develop drug
candidates to further its pipeline of gene therapies in order to
provide novel treatment approaches. Genprex's oncology program
utilizes its unique, proprietary, non-viral ONCOPREX® Nanoparticle
Delivery System, which the Company believes is the first systemic
gene therapy delivery platform used for cancer in humans. ONCOPREX
encapsulates the gene-expressing plasmids using lipid
nanoparticles. The resultant product is administered intravenously,
where it is then taken up by tumor cells that express proteins that
are deficient. The Company's lead product candidate, REQORSA™
(quaratusugene ozeplasmid), is being evaluated as a
treatment for non-small cell lung cancer (NSCLC). REQORSA has a
multimodal mechanism of action that has been shown to interrupt
cell signaling pathways that cause replication and proliferation of
cancer cells; re-establish pathways for apoptosis, or programmed
cell death, in cancer cells; and modulate the immune response
against cancer cells. REQORSA has also been shown to block
mechanisms that create drug resistance. In 2020, the U.S. Food and
Drug Administration (FDA) granted Fast Track Designation for
REQORSA for NSCLC in combination therapy with AstraZeneca's
Tagrisso® (osimertinib) for patients with EFGR mutations whose
tumors progressed after treatment with Tagrisso. In 2021,
the FDA granted Fast Track Designation for REQORSA for NSCLC in
combination therapy with Merck & Co's Keytruda® (pembrolizumab)
for patients whose disease progressed after treatment with
Keytruda.
For more information, please visit the Company's web site at
www.genprex.com or follow Genprex on Twitter,
Facebook and LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are made on the basis of the current beliefs,
expectations and assumptions of management, are not guarantees of
performance and are subject to significant risks and uncertainty.
These forward-looking statements should, therefore, be considered
in light of various important factors, including those set forth in
Genprex's reports that it files from time to time with the
Securities and Exchange Commission and which you should review,
including those statements under "Item 1A – Risk Factors" in
Genprex's Annual Report on Form 10-K for the year ended
December 31, 2021.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
the timing and success of Genprex's clinical trials and regulatory
approvals, including the extent and impact of the COVID-19
pandemic; the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; Genprex's
future growth and financial status; Genprex's commercial and
strategic partnerships, including those with its third party
manufacturers and their ability to successfully perform and scale
up the manufacture of its product candidates; and Genprex's
intellectual property and licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprexs-chief-medical-officer-to-be-featured-as-an-expert-panelist-at-the-33rd-annual-cancer-progress-conference-301542018.html
SOURCE Genprex, Inc.